: iStockAnalyst.com Symbols Feed

Partnerships And Mergers Updates : Wipro Partners with BP, Endo Buys US Rights to Fortesta, Siemens Buys China Metal, Google's Search for Italian Solution

Fri, 28 Aug 2009 18:10:58 GMT

Wipro Technologies, the IT services business of Wipro Ltd. (WIT) announced that it has entered into a five year agreement with BP Plc. (BP) to provide IT Applications Development and Maintenance services for BP’s Fuels Value Chain and Corporate businesses across the globe. Endo Pharmaceuticals (ENDP) signed an agreement with UK-based ProStrakan Group Plc to acquire exclusive rights to commercialize Fortesta in the U.S., where the product is currently under Food and Drug Administration (FDA) review. Siemens Energy, a division of Siemens AG (SI), acquired the majority holding in the Chinese metalworking company Yangtze Delta Manufacturing and the Chinese aluminum foundry GISAP (GIS Steel & Aluminium Products), both headquartered in Hangzhou. The Italian Federation of Newspaper Publishers recently filed an anti-trust complaint against Google Inc. (GOOG). This prompted the Italian Competition Authority to search Google’s Milan offices on Thursday, pursuant to a probe that was ini[More...]

Be Prepared For These Huge Biotech Catalysts In September

Fri, 21 Aug 2009 15:16:00 GMT

Biotech stocks are the most volatile in the world. One-day jumps of 200% and overnight crashes of 90% are commonplace. The biggest culprit behind biotech volatility? The United States Food and Drug Administration, the FDA. Before ending up on pharmacy shelves, every new drug needs to pass through a series of regulatory hurdles dictated by the FDA. Without the FDA's blessing, a drug – no matter how great it may be – cannot make it to market. So an FDA approval can help propel the stock 30% or more. A rejection could send the stock tumbling as much as 90%. Because of this, biotech traders love taking a position ahead of FDA rulings... Which means next month is shaping up to be one of the most event-packed months for biotech traders. I've highlighted six major FDA decisions in the next month below: Date Company FDA Action Drug –[More...]

BioMedReports FDA Calendar: Seven Laggard Trades

Wed, 17 Jun 2009 20:29:05 GMT

Below are seven companies from the BioMedReports.com FDA Calendar database of over 200 entries, which have pending new drug decision(s) at the FDA combined with a stock price that is below its 200-day moving average (200-DMA). The list includes a balanced mix of two large-caps, two mid-caps, and three small-cap stocks which have been laggards in the overall market rally with looming regulatory catalysts in the form of FDA new drug decisions serving as potential upside catalysts. Data Source: Yah (...)[More...]

How To Make 10 Times Your Money in a Single Day

Thu, 21 May 2009 13:31:36 GMT

Kevin Tang is one lucky dude. Tang, the activist manager of the health care hedge fund Tang Capital Partners, has an unusual strategy: liquidate underperforming biotech companies. Here's how it works... The credit crisis – and the ensuing risk-aversion – has driven investors miles away from small biotechs. When sellers far outnumber buyers, a strange phenomenon happens. These stocks get pushed below the amount of cash the companies have in the bank (a condition called "negative enterprise value"). In theory, if you buy the stock at these depressed prices, you can generate instant, guaranteed returns by shutting the company down and returning the existing cash to shareholders. For Kevin Tang, it's not theory. He puts it into practice. Recently, Maryland-based Vanda Pharmaceuticals became Tang's prime target. The company had[More...]

More Cash, Less Debt = Stock Market Gains?

Thu, 23 Apr 2009 13:41:32 GMT

Today there were a couple of posts about how tech stocks are currently especially attractive because they hold plenty of cash and tend to have little debt. Paul Kedrosky initially caught my eye with his post "Tech Cash is King" which in turn pointed me to a story on Bloomberg by Eric Martin. I ran a screen tonight that looked at both cash and debt. Specifically, I screened for a Price-to-Cash ratio under three, a Debt-to-Equity ratio under three and a Market Cap greater than $2.5 million. Based on these criteria, I obtained a list of 136 stocks. Judging from our list, it is absolutely true that many tech stocks do seem to have lots of cash and little debt. What also became apparent as I went through the list is that there[More...]

Penwest Shareholders Want Liquidation

Wed, 04 Mar 2009 17:05:00 GMT

Penwest Pharmaceuticals (NASDAQ: PPCO) shares are trading near their 52-week lows and some investors are growing restless. Tang Capital and Perceptive Life Sciences are two such shareholders that own a combined 40 percent of the troubled company. The investors expressed serious concerns about Penwest’s direction and believe the company should be liquidated to unlock value. In a letter to the board, Tang Capital and Perceptive Life Sciences wrote: We write to express serious concerns about the current direction of Penwest in the hope that you will take[More...]

In Search of Healthcare Diamonds In The Rough

Mon, 12 Jan 2009 04:52:00 GMT

While we are not even halfway through January, the healthcare sector is already active with deal-making, ranging from the rumored $95 buyout of biotech giant Genetech (DNA) by Roche (RHHBY) to Endo's (ENDP) purchase of small-cap, specialty pharma Indevus (IDEV) to Sequenom's (SQNM) $41M offer for emerging diagnostic company EXACT Sciences (EXAS) – which was promptly rebuffed by EXACT's board after the market close on Monday on the promise of a better deal in the works for shareholders. Larger bio-pharma and diagnostic companies are opportunistically looking to expand their product offerings, pipeline prospects, patent portfolios, and drug discovery technology platforms given the huge declines in the stock prices of small/micro-cap stocks in the healthcare sector. With that in mind, I sorted through the ETF Innovators indexes for a list of a dozen[More...]

Weekly Mergers and Acquisitions Report - 01-06-2009

Wed, 07 Jan 2009 13:27:05 GMT

M&A report for $Wavecom (WVCM) - Sierra Wireless (SWIR) , $Indevus Pharmaceuticals (IDEV) - Endo Pharmaceuticals (ENDP), $Datascope Corp. (DSCP) - Getinge AB, Embarq Corporation (EQ) - CenturyTel, Inc. (CTL), $Mentor Corp (MNT) - Johnson Johnson (JNJ[More...]

WBR "PharmaBiotech IP Summit," Philadelphia, May 28-30

Tue, 29 Apr 2008 05:22:18 GMT

Worldwide Business Research will be holding a conference entitled "PharmaBiotech IP Summit," May 28-30 at the Ritz-Carlton in Philadelphia.[More...]

Observations and Stocks for Friday - Apr 11 2008 12:51AM

Fri, 11 Apr 2008 04:45:46 GMT

The interview of the day is with Dmitry Medvedev. Russia’s president-elect talks in depth with FT editor Lionel Barber about the social and economic course for Russia.[More...]

Endo Pharmaceuticals Completes Indevus Tender Offer

Mon, 23 Feb 2009 14:38:42 GMT

Specialty pharmaceutical company Endo Pharmaceuticals has announced the successful completion of the tender offer by its wholly owned subsidiary, BTB Purchaser Inc., to acquire all of the outstanding shares of common stock of Indevus Pharmaceuticals, Inc., a specialty pharmaceutical company.[More...]

Sunoco Elects Its Next CEO

Thu, 17 Jul 2008 07:46:00 GMT

Jul. 17--Sunoco Inc. announced yesterday that it had elected Lynn Laverty Elsenhans, a veteran oil industry executive, as the company's next chief executive officer and president, effective Aug. 8.
Elsenhans replaces CEO and president John G. Drosdick, who turns 65 next month and will be retiring after eight years at the helm.
Drosdick will remain as non-executive chairman until Dec. 31.

[More...]

Endo Pharmaceuticals Announces Resignation of Chief Operating Officer

Wed, 12 Aug 2009 12:26:00 GMT

Endo Pharmaceuticals announced today the resignation of Nancy Wysenski, Endo chief operating officer, effective September 1, to attend to family matters.[More...]

Endo Pharmaceuticals Reports Strong Second Quarter 2009 Financial Results

Thu, 30 Jul 2009 14:46:00 GMT

CHADDS FORD, Pa., July 30 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals today reported financial results for the second quarter of 2009, including a full quarter of results of Indevus Pharmaceuticals, Inc., which Endo acquired during the first quarter.
Net income for the three months ended June 30, 2009, was $30.0 million, compared with $57.1 million in the comparable 2008 period.
As detailed in the supplemental financial information below, adjusted net income for the three months ended June 30, 2009, was $85.9 million, compared with $72.7 million in the same period in 2008.

[More...]

Endo Pharmaceuticals Reports Strong Second Quarter 2009 Financial Results

Thu, 30 Jul 2009 11:48:00 GMT

CHADDS FORD, Pa., July 30 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals today reported financial results for the second quarter of 2009, including a full quarter of results of Indevus Pharmaceuticals, Inc., which Endo acquired during the first quarter.
Net income for the three months ended June 30, 2009, was $30.0 million, compared with $57.1 million in the comparable 2008 period.
As detailed in the supplemental financial information below, adjusted net income for the three months ended June 30, 2009, was $85.9 million, compared with $72.7 million in the same period in 2008.

[More...]

BenchmarkJournal.Com Free Analyst Review for QLGC, NEXM, GERN, ENDP, LOGI and ALXN

Tue, 21 Jul 2009 14:18:00 GMT

Benchmark Journal brings independent company and sector research together, utilizing top financial advisors and investment tactics to provide you with a clear picture of investment opportunities.
Today we began research on QLogic Corp. (NASDAQ: QLGC), NexMed Inc (NASDAQ: NEXM), Geron Corporation (NASDAQ: GERN), Endo Pharmaceuticals Holdings Inc (NASDAQ: ENDP) Logitech International SA (NASDAQ: LOGI) and Alexion Pharmaceuticals Inc. (NASDAQ: ALXN).
To view our research, sign up now and get started with your complimentary subscription.

[More...]

Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)

Fri, 10 Jul 2009 11:56:00 GMT

Bioniche Life Sciences Inc. and Endo Pharmaceuticals jointly announced today that Endo has licensed from Bioniche the exclusive rights to develop and market Urocidin in the U.S. with an option for global rights. Urocidin is a patented formulation of Mycobacterial Cell Wall-DNA Complex developed by Bioniche for the treatment of non-muscle-invasive bladder cancer that is currently undergoing Phase III clinical testing.[More...]

Bioniche Life Sciences Inc. and Endo Pharmaceuticals Inc. Sign Licensing Agreement for Urocidin(TM)

Fri, 10 Jul 2009 11:55:00 GMT

BELLEVILLE, ON and CHADDS FORD, PA, July 10 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC) and Endo Pharmaceuticals Inc. (Nasdaq: ENDP) jointly announced today that Endo has licensed from Bioniche the exclusive rights to develop and market Urocidin(TM) in the U.S. with an option for global rights. Urocidin is a patented formulation of Mycobacterial Cell Wall-DNA Complex (MCC) developed by Bioniche for the treatment of non-muscle-invasive bladder cancer that is currently undergoing Phase III clinical testing.[More...]

Endo Pharmaceuticals to Announce Second Quarter 2009 Financial Results on July 30, 2009

Wed, 01 Jul 2009 20:47:00 GMT

Endo Pharmaceuticals will announce its second quarter financial results on July 30, 2009 and will host a conference call and webcast at 9:00 a.m. ET that day to discuss these results.[More...]

Men with Low Testosterone See Multiple Doctors Before Being Diagnosed; Many Dissatisfied with Current Treatment Options

Wed, 10 Jun 2009 12:26:00 GMT

New Long-Acting Injection in Development[More...]

Penwest and Endo Grant Valeant Pharmaceuticals Exclusive License to Market Opana(r) ER in Canada, Australia and New Zealand

Tue, 09 Jun 2009 11:26:00 GMT

Penwest Pharmaceuticals Co. , Endo Pharmaceuticals and Valeant Pharmaceuticals today announced that Endo has signed an exclusive license with Valeant allowing it to market OPANA ER in Canada, Australia and New Zealand. OPANA ER, the extended release formulation of oxymorphone, was jointly developed by Penwest and Endo.[More...]

Endo Pharmaceuticals to Present at Goldman Sachs 30th Annual Healthcare Conference

Fri, 05 Jun 2009 20:25:00 GMT

Endo Pharmaceuticals announced today that it will present at the Goldman Sachs 30th Annual Healthcare Conference on Wednesday, June 10, 2009 at 4:30 pm Eastern Time. Dave Holveck, President and Chief Executive Officer of Endo, will review the company's products and development programs.[More...]